Navigation Links
MimiVax Appoints Jerry Jacobs Jr. to Board of Directors; SurVaxM Immunotherapy Partnership Opportunities at BIO International June 19-22, 2017.
Date:6/12/2017

MimiVax, LLC, a cancer immunotherapy company today announced that Jerry Jacobs, Jr, co-CEO of Delaware North has joined its Board of Directors. Mr. Jacobs brings deep entrepreneurial insights and business resources to the company.

Mr. Jacobs is co-CEO of Delaware North, one of the most admired family-owned and operated companies in the world. Delaware North is headquartered in Buffalo, New York and has annual revenues of $3 billion, employing more than 55,000 employees on four continents. The University at Buffalo medical school was recently named the Jacobs School of Medicine and Biomedical Sciences, in recognition of the Mr. Jacobs family’s steadfast support.

MimiVax’s lead immunotherapeutic agent, SurVaxM, is currently in a Phase II multicenter clinical trial, and a recently completed interim data analysis puts the program in great position for continued advancement. MimiVax is looking forward to Mr. Jacobs’ strategic guidance for the company and helping it progress much needed new therapies for brain cancer patients.

MimiVax executives will be discussing partnering opportunities for its lead program SurVaxM, as well as pre-clinical pipeline assets: novel anti-survivin monoclonal antibody and CAR-T based approaches for solid tumors at the annual BIO International Conference, taking place between June 19-22, 2017 at the San Diego Convention Center.

Michael Ciesielski, PhD, Chief Scientific Officer; and Anil Goyal, PhD, VP Business Development will be attending the BIO event and hosting partnership meetings.

BIO International Conference : (http://www.bio.org)
Monday-Thursday June 19-22, 2017 ; San Diego Convention Center, San Diego, CA

About MimiVax: MimiVax is a privately held, clinical-stage immuno-oncology company focused on the development and commercialization of immunotherapeutics and targeted therapies for the treatment of cancer. Our proprietary product portfolio is based on technology licensed from Roswell Park Cancer Institute that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Our therapies are designed to break immune tolerance and stimulate immune responses to control tumor growth and recurrence.

About SurVaxM: SurVaxM, our lead immunotherapeutic product, has demonstrated safety and tolerability in a Phase I study in people with malignant gliomas (brain tumors). SurVaxM is currently being evaluated in a Phase II clinical trial in adults with newly diagnosed glioblastoma at five cancer centers: Roswell Park Cancer Institute, Cleveland Clinic, Dana-Farber Cancer Institute, Mass General and Beth Israel Deaconess Hospitals. Also a Phase I clinical trial in combination with REVLIMID® (lenalidomide) as a maintenance therapy for adults with multiple myeloma (a form of blood cancer) is ongoing at Roswell Park.

Read the full story at http://www.prweb.com/releases/mimivax/survaxm/prweb14413751.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PCI Appoints John Davis, PE, to Board
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors
4. SOTIO a.s. Appoints Chiltern International
5. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
6. California Healthcare Institute Appoints Associate Director, Federal Government Relations and Programs
7. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
8. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
9. OHK Medical Devices appoints Mr. Omer Inbar as Chief Executive Officer
10. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
11. TNI BioTech, Inc. Appoints Industry Veteran, Dr. Joseph Fortunak, as a Strategic Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/7/2017)... Phoenix, Arizona (PRWEB) , ... ... ... than 15 years’ experience providing advanced instruments and applications consulting for microscopy ... the in-house expertise in application consulting, Nanoscience Analytical offers a broad range ...
Breaking Biology Technology:
(Date:5/6/2017)... RAM Group , Singaporean based ... in biometric authentication based on a novel  ... to perform biometric authentication. These new sensors are based on ... Ram Group and its partners. This sensor will have ... and security. Ram Group is a next generation ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):